WeighedHealth Research · Free to cite (CC BY 4.0)
GLP-1 & telehealth statistics (2026)
A compilation of the GLP-1 weight-loss numbers people actually search for, with every figure traced to a primary source: the pivotal trials, real 2026 pricing, and how many Americans use these drugs. Free to cite under CC BY 4.0 — please link back to this page.
Last verified 2026-08-08 · compiled by WeighedHealth Editorial
- 0.0%
- top trial weight loss (retatrutide, phase 2)
- 0.0%
- US adults with obesity, 2021-2023
- 0 in 8
- US adults currently on a GLP-1
- $0/mo
- new Ozempic list price from Jan 2027
Weight loss by drug (from the pivotal trials)
- -14.9%
mean body-weight loss on semaglutide 2.4 mg (Wegovy) at 68 weeks
Source: STEP 1, New England Journal of Medicine (2021), PMID 33567185 · verified 2026-08-08
- -20.9%
mean body-weight loss on tirzepatide 15 mg (Zepbound) at 72 weeks
Source: SURMOUNT-1, New England Journal of Medicine (2022), PMID 35658024 · verified 2026-08-08
- -24.2%
mean body-weight loss on retatrutide 12 mg at 48 weeks (investigational, phase 2)
Not FDA-approved; phase 2 result, not a head-to-head comparison.
Source: Retatrutide phase 2, New England Journal of Medicine (2023), PMID 37366315 · verified 2026-08-08
- 86.4%
of semaglutide 2.4 mg patients lost at least 5% of body weight (STEP 1)
Source: STEP 1, New England Journal of Medicine (2021), PMID 33567185 · verified 2026-08-08
- -20.2% vs -13.7%
tirzepatide vs semaglutide at 72 weeks in the first head-to-head obesity trial
Source: SURMOUNT-5, New England Journal of Medicine (2025), PMID 40353578 · verified 2026-08-08
Trial averages describe study populations under controlled conditions, not individuals, and cross-trial figures are not head-to-head unless noted (SURMOUNT-5 is the exception). See our drug explainers for context.
Cost & pricing (2026)
- ~$1,000/mo
Ozempic list price (wholesale acquisition cost) in 2026 before any discount
Source: Novo Nordisk list pricing · verified 2026-08-08
- $675/mo
announced new Ozempic list price for all doses, effective January 1, 2027 (~35% cut)
Source: Novo Nordisk pricing announcement · verified 2026-08-08
- $499/mo
standard NovoCare self-pay price for most Ozempic doses ($199 for the first two starter fills)
Source: NovoCare Pharmacy self-pay program · verified 2026-08-08
- $25/mo
lowest Ozempic cost with commercial insurance plus the manufacturer savings card (per-fill caps apply)
Not available to people on Medicare, Medicaid, or other government plans.
Source: Novo Nordisk Ozempic Savings Card terms · verified 2026-08-08
Prevalence & use (United States)
- 40.3%
of US adults had obesity in 2021-2023 (measured, not self-reported)
Source: CDC NCHS Data Brief No. 508 (Sept 2024) · verified 2026-08-08
- 9.4%
of US adults had severe obesity in 2021-2023
Source: CDC NCHS Data Brief No. 508 (Sept 2024) · verified 2026-08-08
- 1 in 8
US adults (12%) say they are currently taking a GLP-1 drug
Source: KFF Health Tracking Poll, May 2024 · verified 2026-08-08
- 1 in 5
US adults (18%) say they have taken a GLP-1 drug at some point
Source: KFF Health Tracking Poll, May 2024 · verified 2026-08-08
How to cite this page
These figures are free to reuse under CC BY 4.0. If a number here helps your article, a link back to this page is the attribution we ask for. For a stat on deadline, email [email protected].
Every value links to its primary source (FDA labels, NEJM trials via PubMed, CDC, and KFF). We do not aggregate from secondary summaries. See our methodology.